Profile data is unavailable for this security.
About the company
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. It also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
- Revenue in USD (TTM)4.38bn
- Net income in USD-1.04bn
- Incorporated2007
- Employees16.90k
- LocationCatalent Inc14 Schoolhouse RdSOMERSET 08873-1213United StatesUSA
- Phone+1 (732) 537-6200
- Fax+1 (732) 537-6480
- Websitehttps://www.catalent.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avidity Biosciences Inc | 10.60m | -252.45m | 5.51bn | 253.00 | -- | 4.23 | -- | 520.29 | -2.95 | -2.95 | 0.1231 | 11.17 | 0.0108 | -- | 17.92 | 41,893.28 | -25.78 | -31.61 | -27.61 | -34.45 | -- | -- | -2,381.82 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Jazz Pharmaceuticals PLC | 3.91bn | 394.92m | 6.75bn | 2.80k | 18.79 | 1.79 | 6.47 | 1.73 | 5.82 | 5.82 | 57.26 | 60.94 | 0.3457 | 0.6914 | 5.98 | 1,396,387.00 | 3.51 | 1.48 | 3.94 | 1.62 | 89.39 | 88.79 | 10.14 | 4.26 | 2.02 | 2.27 | 0.6027 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Elanco Animal Health Inc | 4.49bn | -1.26bn | 7.25bn | 9.30k | -- | 1.22 | -- | 1.61 | -2.55 | -2.55 | 9.09 | 12.02 | 0.3039 | 1.22 | 4.49 | 483,010.80 | -8.49 | -3.27 | -9.33 | -3.65 | 55.19 | 54.28 | -27.94 | -11.53 | 1.75 | 1.11 | 0.4886 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Intra-Cellular Therapies Inc | 564.53m | -84.30m | 7.70bn | 610.00 | -- | 6.73 | -- | 13.64 | -0.8629 | -0.8629 | 5.75 | 10.84 | 0.5551 | 1.33 | 4.67 | 925,452.40 | -8.29 | -38.27 | -9.47 | -42.77 | 92.72 | -- | -14.93 | -128.42 | 7.69 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Roivant Sciences Ltd | 158.30m | 4.74bn | 8.42bn | 845.00 | 2.04 | 1.55 | 1.81 | 53.16 | 5.57 | 5.57 | 0.1979 | 7.35 | 0.0367 | 0.8018 | 2.71 | 187,340.80 | 106.95 | -- | 126.66 | -- | 90.32 | -- | 2,916.27 | -- | 27.75 | -- | 0.052 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
| Catalent Inc | 4.38bn | -1.04bn | 10.99bn | 16.90k | -- | 3.03 | -- | 2.51 | -5.75 | -5.75 | 24.14 | 20.02 | 0.4268 | 4.88 | 3.01 | 259,230.80 | -10.16 | 0.0124 | -11.61 | 0.014 | 21.75 | 28.93 | -23.81 | 0.0278 | 1.93 | 0.6681 | 0.5765 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
| Incyte Corp | 3.86bn | 97.30m | 13.00bn | 2.52k | 190.85 | 4.31 | 70.47 | 3.37 | 0.3536 | 0.3536 | 17.18 | 15.64 | 0.7097 | 3.58 | 5.60 | 1,528,136.00 | 1.79 | 9.07 | 2.31 | 11.02 | 93.66 | 94.97 | 2.52 | 13.68 | 1.84 | -- | 0.0108 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Biomarin Pharmaceutical Inc | 2.59bn | 256.59m | 13.23bn | 3.40k | 52.40 | 2.50 | 36.46 | 5.11 | 1.33 | 1.33 | 13.28 | 27.77 | 0.3798 | 0.4778 | 3.98 | 761,069.70 | 3.76 | 0.7116 | 4.29 | 0.8079 | 80.07 | 76.30 | 9.91 | 2.05 | 1.95 | -- | 0.1708 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Viatris Inc | 15.24bn | -646.50m | 13.83bn | 38.00k | -- | 0.7085 | 6.42 | 0.9077 | -0.5433 | -0.5433 | 12.68 | 16.36 | 0.3242 | 2.30 | 5.25 | 401,031.60 | -1.38 | 0.0887 | -1.62 | 0.1061 | 42.78 | 40.29 | -4.24 | 0.2891 | 1.02 | 2.48 | 0.4668 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Royalty Pharma plc | 2.24bn | 673.24m | 16.47bn | 89.00 | 18.45 | 1.92 | 19.61 | 7.36 | 1.50 | 1.50 | 3.74 | 14.42 | 0.1287 | -- | 76.10 | 25,141,870.00 | 5.92 | 9.57 | 7.77 | 12.42 | -- | -- | 46.02 | 67.80 | -- | -- | 0.4381 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 19.63m | 10.85% |
| Nomura Securities Co., Ltd. (Private Banking)as of 31 Mar 2024 | 11.26m | 6.22% |
| Capital Research & Management Co. (World Investors)as of 30 Apr 2024 | 9.66m | 5.34% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 9.52m | 5.26% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 9.45m | 5.22% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 7.42m | 4.10% |
| Veritas Asset Management LLPas of 31 Mar 2024 | 6.03m | 3.33% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 4.89m | 2.70% |
| Geode Capital Management LLCas of 30 Jun 2024 | 4.31m | 2.38% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 4.10m | 2.27% |
